{"id":72273,"date":"2024-07-29T08:00:10","date_gmt":"2024-07-29T08:00:10","guid":{"rendered":"http:\/\/76616b3d9d810f49bf17c5efc2e884aa"},"modified":"2024-07-29T08:00:10","modified_gmt":"2024-07-29T08:00:10","slug":"diabetes-patients-now-have-access-to-first-generic-glp-1-medication-more-accessible-and-affordable","status":"publish","type":"post","link":"https:\/\/wp.timesamerica.net\/diabetes-patients-now-have-access-to-first-generic-glp-1-medication-more-accessible-and-affordable\/","title":{"rendered":"Diabetes patients now have access to first generic GLP-1 medication: \u2018More accessible and affordable\u2019"},"content":{"rendered":"\n
Ozempic, Wegovy and other GLP-1 medications have gained widespread popularity for weight loss and diabetes control<\/u><\/span> in recent years \u2014 but the spike in demand has made it difficult for some people to get the drugs.<\/p>\n To help eliminate supply chain snafus, the first-ever generic GLP-1 \u2014 a duplicate of Victoza \u2014 launched on June 25.<\/p>\n Manufactured by Novo Nordisk and distributed and sold by Israel-based Teva Pharmaceuticals, Victoza is an injectable medication intended to treat type 2 diabetes. It has also been shown to promote weight loss<\/u><\/span> in certain patients, according to Teva.<\/p>\n OZEMPIC AND WEGOVY COULD DOUBLE AS KIDNEY DISEASE TREATMENT, STUDY SUGGESTS<\/u><\/strong><\/span><\/p>\n While Ozempic and Wegovy contain semaglutide and Mounjaro has tirzepatide, Victoza has liraglutide as its active ingredient.<\/p>\n “By launching an authorized generic for Victoza (liraglutide injection 1.8mg), we are providing patients with type 2 diabetes another option for this important treatment,” said Ernie Richardsen, SVP, head of U.S. commercial generics at Teva, in a press release from the company.<\/p>\n